Table 3.

Top five attributes of an ideal therapy and greatest unmet therapeutic needs

Ideal therapy		Unmet therapeutic needs
Dermatologists psoriasis	Rheumatologists ‒ PsA	Dermatologists ‒ psoriasis	Rheumatologists ‒ PsA
No increased risk of serious infection or cancer (36.6%)	Improvement in joint pain (39.7%)	Improved efficacy (35.5%)	Improved efficacy (34.2%)
Manageable tolerability profile (17.4%)	Long‐term safety (22.1%)	Improved long‐term safety (33.5%)	A new mechanism of action (23.4%)
Provides clearance of at least 50% (18.4%)	Improvement in daily activity (17.2%)	A new mechanism of action (11.8%)	Improved long‐term safety (19.0%)
Improved access to therapy (11.0%)	Improved access to therapy (11.5%)	Another oral option (11.5%)	Another oral option (15.4%)
Oral administration (12.0%)	Oral administration (7.2%)	Improved tolerability (7.4%)	Improved tolerability (8.0%)

PsA, psoriatic arthritis.